Investors

Investors
<picture><source type="image/webp" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/18e05/Image-1.webp 740w,/static/2cf241996b0d6d9b54351b76891640b8/81bef/Image-1.webp 1480w,/static/2cf241996b0d6d9b54351b76891640b8/2d0b8/Image-1.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/bbd3f/Image-1.jpg 740w,/static/2cf241996b0d6d9b54351b76891640b8/087e6/Image-1.jpg 1480w,/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg 2960w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate Governance
Articles of Association
General meeting
Board of Directors
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Scientific advisory board
Archived transactions
Shareholder & stock info
Share monitor
Shareholders
Analyst coverage
Financial reports
Financial calendar
Letter from the CEOIn Q3 of 2022, we brought Mendus in a strong position to reach its upcoming milestones. We have been preparing for presentation of the updated survival results from our ADVANCE II Phase 2 trial, which evaluates DCP-001 as a novel immunotherapy in AML. The data will be presented in less than a month from now at ASH, the world’s largest haematology conference. Also at ASH, we will present extensive immunomonitoring data, which have been collected as part of the ADVANCE II trial to deepen our understanding of the effect of DCP-001 on the immune system, residual disease and, most importantly, disease-free and overall survival.
To read the full letter from the CEO, please click here.
Latest Company PresentationView the latest company presentation
 
Latest press releasesNovember 2022Regulatory Release
Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 18 November 2022
At the Extraordinary General Meeting (the “EGM”) of Mendus AB (publ), reg. no 556629-1786, (the “Company”) on 18 November 2022 the EGM adopted, inter alia, the following resolution. For more detailed...
Learn more
November 2022Regulatory Release
Mendus AB: Mendus to host key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Virtual webinar to take place Wednesday, November 30, 2022 @ 1 PM ET / 7PM CET  Upcoming data from Phase 2 ADVANCE II trial of DCP-001 at ASH in December 2022    Mendus AB (“Mendus” publ; IMMU.ST, or...
Learn more
Upcoming EventsDecember 2022
64th American Society of Hematology Annual Meeting
Updated results from the Phase 2 ADVANCE II clinical trial will be presented in an oral presentation on December 12. In addition, the company will present immunomonitoring data in a separate poster presentation on December 10.  
Learn more
November 2022
Key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Mendus will host a key opinion leader (KOL) webinar highlighting the current state of maintenance treatment and immunotherapy in acute myeloid leukemia (AML) patients. The event will feature two leading clinical experts, Assoc. Prof. Dr. Amer Zeidan, MBBS, MHS, from the Yale School of Medicine, and Prof. Dr. med. Uwe Platzbecker, from the Leipzig University Hospital.
Learn more

Contact
Telephone+46 (0)8 732 8400
Emailinfo@mendus.com
<picture><source type="image/webp" srcSet="/static/411b7857055b0888002108e1bcc9e280/e64f1/heado.webp 100w,/static/411b7857055b0888002108e1bcc9e280/8b00d/heado.webp 200w,/static/411b7857055b0888002108e1bcc9e280/9c0a1/heado.webp 400w,/static/411b7857055b0888002108e1bcc9e280/88f3e/heado.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg" srcSet="/static/411b7857055b0888002108e1bcc9e280/93e3f/heado.jpg 100w,/static/411b7857055b0888002108e1bcc9e280/839ae/heado.jpg 200w,/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg 400w,/static/411b7857055b0888002108e1bcc9e280/a677a/heado.jpg 800w" alt="&lt;p&gt;Image of old buildings by a dock with boats laying in the water in the foreground.&lt;/p&gt;
"/></picture>
Head OfficeVästra Trädgårdsgatan 15

111 53 Stockholm

Sweden
<picture><source type="image/webp" srcSet="/static/99d97027eda87168e92d8d30678ace5b/e64f1/rdo.webp 100w,/static/99d97027eda87168e92d8d30678ace5b/8b00d/rdo.webp 200w,/static/99d97027eda87168e92d8d30678ace5b/9b01d/rdo.webp 400w,/static/99d97027eda87168e92d8d30678ace5b/08dc5/rdo.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg" srcSet="/static/99d97027eda87168e92d8d30678ace5b/93e3f/rdo.jpg 100w,/static/99d97027eda87168e92d8d30678ace5b/839ae/rdo.jpg 200w,/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg 400w,/static/99d97027eda87168e92d8d30678ace5b/3f065/rdo.jpg 800w" alt="&lt;p&gt;City image from a walkway, with a church and tall buildings in the background.&lt;/p&gt;
"/></picture>
R&D OfficesEmmy Noetherweg 2K 

2333 BK Leiden

The Netherlands
<picture><source type="image/webp" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/e64f1/go.webp 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/8b00d/go.webp 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/9c0a1/go.webp 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/88f3e/go.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/93e3f/go.jpg 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/839ae/go.jpg 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/a677a/go.jpg 800w" alt="&lt;p&gt;Overview image of a city, shot in low sunlight from a far distance.&lt;/p&gt;
"/></picture>
Gothenburg OfficeMendus C/O AstraZeneca BioventureHub

Pepparedsleden 1

431 83 Mölndal

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1479869476-oFHjH8dKSUNTYkCcFdtG32:before { opacity: 1; background-image: url('/static/a32348a89302674e113dc101e935b7b3/afb86/about-us-mobile.png'); }

News & eventsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
News & Events

Letter from the CEO

Latest Company Presentation

Latest press releases

Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 18 November 2022

Mendus AB: Mendus to host key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission

Upcoming Events

64th American Society of Hematology Annual Meeting

Key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission

Contact

Telephone

Email

Head Office

R&D Offices

Gothenburg Office

News & events

Keep up to date